ProLynx: Funding, Investors & Team (Oct 2026)
ProLynx is a biotechnology company that develops proprietary drug-delivery technologies designed to extend the half-life of therapeutic molecules, including peptides, proteins, and small molecules, so they maintain effective levels in the body for controlled periods. The company’s core platform uses β-eliminative linkers that are programmed to release native drugs from macromolecular carriers (such as circulating polymers or hydrogel microspheres) at predictable rates, enabling sustained release over weeks to months. ProLynx applies this technology to create long-acting therapeutic candidates and partners with pharmaceutical firms and academic researchers to design and test novel drug conjugates. Its pipeline includes extended-duration therapies for metabolic and obesity indications, with a focus on formulations engineered for monthly or quarterly dosing schedules.
ProLynx has raised $70.0M across 1 funding round on record, the most recent a Series A of $70.0M announced in Dec 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ProLynx Company Profile and Key Stats
Latest funding round on record: Dec 2025.
ProLynx Funding Rounds
ProLynx Founders and Leadership Team
Contact details for the ProLynx team: 1 of 1 has an email address on file.
Start 14-day free trial →ProLynx Funding Compared to Other Biotechnology Startups
ProLynx's latest round of $70.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ProLynx in Biotechnology and San Francisco
Companies Similar to ProLynx
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
ProLynx Funding FAQs
What does ProLynx do?
ProLynx is a biotechnology company that develops proprietary drug-delivery technologies designed to extend the half-life of therapeutic molecules, including peptides, proteins, and small molecules, so they maintain effective levels in the body for controlled periods. The company’s core platform uses β-eliminative linkers that are programmed to release native drugs from macromolecular carriers (such as circulating polymers or hydrogel microspheres) at predictable rates, enabling sustained release over weeks to months. ProLynx applies this technology to create long-acting therapeutic candidates and partners with pharmaceutical firms and academic researchers to design and test novel drug conjugates. Its pipeline includes extended-duration therapies for metabolic and obesity indications, with a focus on formulations engineered for monthly or quarterly dosing schedules.
How much funding has ProLynx raised?
ProLynx has raised $70.0M across 1 round on record. The most recent is a Series A of $70.0M announced in Dec 2025.
When did ProLynx last raise funding?
ProLynx's most recent funding round on record is a Series A of $70.0M, announced in Dec 2025.
Who founded ProLynx?
FundedIQ lists Gary Ashley (Founder) at ProLynx.
Where is ProLynx headquartered?
ProLynx is based in San Francisco, California, United States.
How many employees does ProLynx have?
ProLynx is in the 11-50 employee band.
How does ProLynx's funding compare to other Biotechnology startups?
ProLynx's latest round of $70.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ProLynx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ProLynx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.